CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

21-105

MICROBIOLOGY REVIEW

APR 28 2000

DIVISION 0F ANTI-INFECTIVE DRUG PRODUCTS (HFD-520)
Clinical Microbiological Review

NDA#: 21-105 **REVIEW #**: 1 **REVIEW COMPLETED**: 04/27/00

DOCUMENT DATE	CDER DATE	ASSIGNED DATE
02/18/99	02/19/99	06/21/99

NAME & ADDRESS OF APPLICANT:
Able Laboratories, Inc.
6 Hollywood Court
South Plainfield, New Jersey 07080

CONTACT PERSON:
Peter J. Mione
Vice President,
Clinical and Regulatory Affairs – DynaGen, Inc.
Tel: (617) 491-2527 / FAX: (617) 354-3902

DRUG PRODUCT NAME:

Proprietary:	ZOTRIM™ *UTI* Therapy Tablets
Non-Proprietary/USAN:	trimethoprim/sulfamethoxazole & phenazopyridine HCl
Code Names:	N/A
CAS Nos:	*CAS-738-70-5 / CAS-723-46-6 / CAS-136-40-3*

CHEMICAL NAME, STRUCTURAL & MOLECULAR FORMULA, MOL. W.T.:

Trimethoprim:

Chemical Name/Structure	=	See 1998 USAN (Page 759)
Molecular Formula	=	$C_{14}H_{18}N_4O_3$
Molecular Weight	=	290.32

and

Sulfamethoxazole

Chemical Name/Structure	=	See 1998 USAN (Page 693)
Molecular Formula	=	$C_{10}H_{11}N_3O_3S$
Molecular Weight	=	253.28

and

Phenazopyridine HCl

Chemical Name/Structure	=	See 1998 USAN (Page 566)
Molecular Formula	=	$C_{11}H_{11}N_5.HCl$
Molecular Weight	=	249.70

__1__ page(s) have been removed because it contains trade secret and/or confidential information that is not disclosable.

APR 28 2000

DIVISION 0F ANTI-INFECTIVE DRUG PRODUCTS (HFD-520)
Clinical Microbiological Review

NDA#: 21-105 **REVIEW #**: 1 **REVIEW COMPLETED**: 04/27/00

DOCUMENT DATE	CDER DATE	ASSIGNED DATE
02/18/99	02/19/99	06/21/99

NAME & ADDRESS OF APPLICANT:
Able Laboratories, Inc.
6 Hollywood Court
South Plainfield, New Jersey 07080

CONTACT PERSON:
Peter J. Mione
Vice President,
Clinical and Regulatory Affairs – DynaGen, Inc.
Tel: (617) 491-2527 / FAX: (617) 354-3902

DRUG PRODUCT NAME:

Proprietary:	ZOTRIM™ *UTI* Therapy Tablets
Non-Proprietary/USAN:	trimethoprim/sulfamethoxazole & phenazopyridine HCl
Code Names:	N/A
CAS Nos:	*CAS-738-70-5 / CAS-723-46-6 / CAS-136-40-3*

CHEMICAL NAME, STRUCTURAL & MOLECULAR FORMULA, MOL. W.T.:

Trimethoprim:

Chemical Name/Structure	=	See 1998 USAN (Page 759)
Molecular Formula	=	$C_{14}H_{18}N_4O_3$
Molecular Weight	=	290.32

and

Sulfamethoxazole

Chemical Name/Structure	=	See 1998 USAN (Page 693)
Molecular Formula	=	$C_{10}H_{11}N_3O_3S$
Molecular Weight	=	253.28

and

Phenazopyridine HCl

Chemical Name/Structure	=	See 1998 USAN (Page 566)
Molecular Formula	=	$C_{11}H_{11}N_5.HCl$
Molecular Weight	=	249.70

DOSAGE FORM: Tablets
ROUTE OF ADMINISTRATION: Oral

STRENGTH:
- Each DS (double strength) Tablet contains 160 mg trimethoprim and 800 mg sulfamethoxazole; and
- Each phenazopyridine HCl Tablet contains 200 mg phenazopyridine.

DISPENSED: _x_ Rx ___ OTC

NDA Suitability Petition/DESI/Patent Status: See NDA 21-105, Vol. 1.1, Section i.B., *Patent Information/Certification*, on Pages 12 to 34.

PHARMACOLOGICAL CATEGORY/INDICATION:
Trimethoprim (a pyrimidine analog) and sulfamethoxazole (derived from sulfanilamide) are synthetic antibacterial agents; and

Phenazopyridine HCl is a urinary tract analgesic drug/

A combination of 2-drug products (Trimethoprim-Sulfamethoxazole DS Tablets & Phenazopyridine Hydrochloride Tablets) packaged in a single blister card package intended for the treatment of uncomplicated urinary tract infection.

AMENDMENT(S): N/A

RELATED DOCUMENTS:

[redacted]

NDA 17-376, Septra® DS, Burroughs Wellcome (currently Glaxo Wellcome), approved on 02/12/76;
NDA 17-377, Bactrim™ (trimethoprim/sulfamethoxazole) DS Tablets, Hoffmann-LaRoche (currently Roche Laboratories), approved in 03/01/78;
70037, Sulfamethoxazole-Trimethoprim DS Tablets, approved on 06/02/87;

[redacted]

NDA 70-943, PROLOPRIM®, Trimethoprim Tablets, Oral, 100 mg and 200 mg trimethoprim per tablet, approved on 7/14/82;
Glaxo Wellcome's supplemental amendment, dated 4/22/97, in response to the Agency's "approvable" letter to Burroughs Wellcome Company's, dated 11/28/90 on NDA 17-943/SLR-010; and
NDA 17-943/SLR-014, PROLOPRIM® (trimethoprim) Tablets, Agency's "acceptable" FPL letter, dated 5/20/97, and requesting Glaxo Wellcome to submit a new Supplement to revise the **Microbiology** subsection and the **DOSAGE AND ADMINISTRATION** section.

CONSULTS: N/A

REMARKS/COMMENTS:

In the past, the 2-drug products have been given separately for treatment of uncomplicated UTI. Now, these 2-drug products are now being packaged in a single blister card package intended for the treatment of uncomplicated urinary tract infection.

CONCLUSIONS:

From the microbiological perspective, an approval letter should be issued to Able Laboratories, Inc. after negotiation of their applicant's revised draft labeling, as found on pages 86 & 87 and 98, in the NDA's microbiology and references portion. This includes all the Agency's recommendations on the labeling as indicated in the **PACKAGE INSERT – CLINICAL PHARMACOLOGY – Microbiology and Susceptibility Testing Methods** subsections, and the **REFERENCES** section, on pages 15 to 19, at the end of this Clinical Microbiological Review.

APPEARS THIS WAY
ON ORIGINAL

15 page(s) have been removed because it contains trade secret and/or confidential information that is not disclosable.